AbCellera Biologics Inc.

NasdaqGS:ABCL Stock Report

Market Cap: US$807.4m

AbCellera Biologics Dividend

Dividend criteria checks 0/6

AbCellera Biologics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield0.3%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$0.52
Dividend yield forecast0%

Recent dividend updates

No updates

Recent updates

AbCellera: A Waiting Game With High Uncertainty

Aug 23

Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

May 29
Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

AbCellera: Cash Providing Shelter From Market Weakness

May 16

AbCellera: Victim Of Its Own Success

Feb 28

AbCellera Biologics: Continuing To Expand Partnerships

Feb 13

Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

Feb 04
Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

Nov 29
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

AbCellera Biologics: Many Reasons To Own This Undervalued Stock

Sep 06

AbCellera Biologics: COVID Antibody Set To Provide Continued Funding

Aug 14

AbCellera partnering with Atlas Ventures on development of therapeutic antibodies

Aug 03

AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying

Jun 06

Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

May 13
Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

May 07
Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment

Apr 22

AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm

Feb 11

AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues

Dec 05

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ABCL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ABCL's dividend payments have been increasing.


Dividend Yield vs Market

AbCellera Biologics Dividend Yield vs Market
How does ABCL dividend yield compare to the market?
SegmentDividend Yield
Company (ABCL)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.3%
Industry Average (Life Sciences)0.3%
Analyst forecast (ABCL) (up to 3 years)0%

Notable Dividend: Unable to evaluate ABCL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ABCL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ABCL's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ABCL has not reported any payouts.


Discover strong dividend paying companies